website-logo (2).png
Recombinant Proteins Market Predicted to Garner US$ 704.6 Bn By 2033, At CAGR 13.5% |
20 févr. 2024 01h01 HE |
New York, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The recombinant proteins market was valued at USD 205.0 billion in 2023 with significant growth and is projected to reach at USD 704.6 billion by 2033...
website-logo (2).png
Oncology Drugs Market to Surpass USD 332.4 Bn by 2033, Driven by Individualized Treatment | Report
20 févr. 2024 00h53 HE |
New York, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The oncology drugs market was valued at USD 176.6 billion in 2023 with a significant growth and is projected to reach at USD 332.4 billion by 2033 with an...
[Latest] Global Roasted Coffee Market Size/Share Worth USD 73.46 Billion by 2032 at a 5.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
19 févr. 2024 12h30 HE | Custom Market Insights
Austin, TX, USA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Roasted Coffee Market Size, Trends and Insights By Type (Arabica, Robusta), By...
Vaccinex logo
Vaccinex, Inc. Announces Reverse Stock Split
15 févr. 2024 08h00 HE | Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Erasmus Medical Center
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
14 févr. 2024 08h55 HE | AIM ImmunoTech Inc.
OCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus Medical Center (“Erasmus...
finacialnews-logo-final-01 (2).png
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
14 févr. 2024 08h30 HE | FN Media Group LLC
PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on...
BioNTech and Autolus
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs 
08 févr. 2024 05h45 HE | BioNTech SE
Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market...
BioNTech und Autolus
BioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-Programme
08 févr. 2024 05h45 HE | BioNTech SE
Die Unternehmen nutzen in der strategischen Zusammenarbeit Produktionskapazitäten, kommerzielle Infrastruktur sowie Technologien mit dem Ziel, die autologen CAR-T-Programme beider Unternehmen...
genenta logo positivo.png
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
08 févr. 2024 05h00 HE | GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of...
NOVARTIS logo.jpg
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
05 févr. 2024 16h45 HE | Novartis Pharma AG
Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or...